NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Apollomics Inc. APLM
5 fiscal years on record · USD · FY2024 reported · SEC filings only
Growth
—
Revenue, FY2024 · full 5-year series below
Revenue $M
Net income $M
FY2024 · Revenue 0.0 · Net income -53.9
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
Not available in our data for this period.
The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | · | · | 0.0 | · | · |
| EBITDA $B | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Net income $B | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −52.80 | −231.99 | −844.95 | −3.37 | −0.21 |
| Dividend / sh $ | · | · | · | · | · |
| Payout % | · | · | · | · | · |
| ROE % | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 1 failures in 15 reconciliationsAUDITED
Reconciled in 4 of 19 fiscal years. 61 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020